Ergomar

Vascular Headaches, Postpartum state, Cluster Headache + 2 more
Treatment
4 FDA approvals
20 Active Studies for Ergomar

What is Ergomar

ErgotamineThe Generic name of this drug
Treatment SummaryErgotamine is a drug found in ergot, a fungus that grows on rye grain. It is used to treat migraine headaches by narrowing the blood vessels. Ergotamine is classified as an alpha-1 selective adrenergic agonist and works by stimulating certain receptors in the body.
Cafergotis the brand name
image of different drug pills on a surface
Ergomar Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Cafergot
Ergotamine
1953
15

Approved as Treatment by the FDA

Ergotamine, also known as Cafergot, is approved by the FDA for 4 uses which include Migraine and Cluster Headache .
Migraine
Cluster Headache
Vascular Headaches
Used to treat Vascular Headaches in combination with Caffeine
Neuralgia

Effectiveness

How Ergomar Affects PatientsErgotamine is a drug that affects multiple systems in the body. It constricts peripheral and cranial blood vessels, influences the activity of tryptaminergic, dopaminergic, and alpha adrenergic receptors, and can stimulate the uterus. It is thought to help with migraine pain by decreasing the pulsations in the cranial arteries and reducing blood flow in the extracranial area. It does not, however, affect cerebral hemispheric blood flow.
How Ergomar works in the bodyErgotamine works to stop migraines by constricting blood vessels in the head and blocking the release of pro-inflammatory chemicals from nerves in the trigeminal system. This is done by stimulating 5-HT1D receptors, which are located on both blood vessels and nerve endings.

When to interrupt dosage

The recommended dose of Ergomar is contingent upon the acknowledged condition, like Postpartum state, Cluster Headache and Uterine Atony. The magnitude of dosage varies as indicated by the mode of delivery noted in the table beneath.
Condition
Dosage
Administration
Migraine
1.0 mg, , 2.0 mg, 0.6 mg, 0.3 mg, 9.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Rectal, Suppository, Suppository - Rectal, Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Tablet - Sublingual, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral, Aerosol, Aerosol - Oral
Vascular Headaches
1.0 mg, , 2.0 mg, 0.6 mg, 0.3 mg, 9.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Rectal, Suppository, Suppository - Rectal, Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Tablet - Sublingual, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral, Aerosol, Aerosol - Oral
Cluster Headache
1.0 mg, , 2.0 mg, 0.6 mg, 0.3 mg, 9.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Rectal, Suppository, Suppository - Rectal, Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Tablet - Sublingual, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral, Aerosol, Aerosol - Oral
Postpartum state
1.0 mg, , 2.0 mg, 0.6 mg, 0.3 mg, 9.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Rectal, Suppository, Suppository - Rectal, Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Tablet - Sublingual, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral, Aerosol, Aerosol - Oral
Uterine Inertia
1.0 mg, , 2.0 mg, 0.6 mg, 0.3 mg, 9.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Rectal, Suppository, Suppository - Rectal, Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Tablet - Sublingual, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral, Aerosol, Aerosol - Oral

Warnings

Ergomar Contraindications
Condition
Risk Level
Notes
Liver Diseases
Do Not Combine
Renal Insufficiency
Do Not Combine
Coronary Heart Disease
Do Not Combine
Peripheral Vascular Disease
Do Not Combine
Pulse Frequency
Do Not Combine
Hypertensive disease
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Ergomar.
Common Ergomar Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Major
The metabolism of (R)-warfarin can be decreased when combined with Ergotamine.
(S)-Warfarin
Major
The metabolism of (S)-Warfarin can be decreased when combined with Ergotamine.
1,2-Benzodiazepine
Major
The metabolism of 1,2-Benzodiazepine can be decreased when combined with Ergotamine.
3,5-diiodothyropropionic acid
Major
The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Ergotamine.
4-Bromo-2,5-dimethoxyphenethylamine
Major
Ergotamine may increase the hypertensive and vasoconstricting activities of 4-Bromo-2,5-dimethoxyphenethylamine.
Ergomar Toxicity & Overdose RiskSigns of an overdose on a drug may include irritation, nausea, vomiting, headache, diarrhea, increased thirst, cold skin, itching, weak heartbeat, numbness and tingling in the limbs, and confusion.
image of a doctor in a lab doing drug, clinical research

Ergomar Novel Uses: Which Conditions Have a Clinical Trial Featuring Ergomar?

69 active clinical trials are currently being conducted to assess the potential of Ergomar to alleviate Migraine, Uterine Atony and Postpartum state disorders.
Condition
Clinical Trials
Trial Phases
Vascular Headaches
0 Actively Recruiting
Migraine
51 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Postpartum state
11 Actively Recruiting
Not Applicable, Phase 4, Phase 1
Uterine Inertia
1 Actively Recruiting
Phase 2
Cluster Headache
2 Actively Recruiting
Phase 1, Phase 2

Ergomar Reviews: What are patients saying about Ergomar?

5Patient Review
4/3/2012
Ergomar for Migraine Headache
This medication always abort my migraines, and I'm so thankful for that!
5Patient Review
2/1/2008
Ergomar for Migraine Headache
4.7Patient Review
2/6/2008
Ergomar for Migraine Headache
I'm using this medication for the first time tonight in hopes that it will help to reduce my migraines and vomiting. So far, I don't have much to go off of.
4.3Patient Review
6/12/2011
Ergomar for Migraine Headache
This medication quickly and effectively relieved my migraine pain.
3.7Patient Review
1/6/2008
Ergomar for Migraine Headache
3.7Patient Review
1/6/2008
Ergomar for Migraine Headache
3Patient Review
2/19/2008
Ergomar for Migraine Headache
Ergomar has been working well for me for a long time. I appreciate that it has a gentle onset and that I don't need water to take it.
2.3Patient Review
6/6/2021
Ergomar for Migraine Headache
Unfortunately, this pill did not help with my migraines. On the contrary, it made me feel worse by causing heart and breathing problems. I will not be taking any more of this medication.
1Patient Review
7/29/2011
Ergomar for Migraine Headache
I'm not a fan of this treatment
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ergomar

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What ergotamine is used for?

"Dihydroergotamine and ergotamine areReduce the size of blood vessels and relieve the pain of throbbing headaches, such as migraine and cluster headaches. Dihydroergotamine and ergotamine are not painkillers that will relieve any other type of pain."

Answered by AI

What is Ergomar used for?

"Ergomar is an ergot alkaloid used to treat a migraine type headache that has already begun, but will not prevent migraine headaches or reduce the number of attacks."

Answered by AI

What is the drug Cafergot used for?

"This drug is a combination of two medications, ergotamine and caffeine, which are used to relieve pain from migraines and cluster headaches. The ergotamine works by constricting the blood vessels in the head, which alleviates the pain."

Answered by AI

Is Ergomar a triptan?

"Ergomar and triptan medications like Imitrex and Maxalt have similar mechanism of action and side effects. Simultaneous use of these medications can lead to increased blood pressure and other serious side effects."

Answered by AI

Clinical Trials for Ergomar

Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA
The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.
Waitlist Available
Has No Placebo
University of California San Diego
Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Waitlist Available
Has No Placebo
Johns Hopkins MedicineRisheng Xu, MD, PhDMedtronic
Have you considered Ergomar clinical trials? We made a collection of clinical trials featuring Ergomar, we think they might fit your search criteria.Go to Trials
Image of Women's College Hospital in Toronto, Canada.

MOVIN Care Platform for Postpartum Depression

18+
Female
Toronto, Canada
Depression, anxiety, and related disorders such as post-traumatic stress and obsessive compulsive disorder affect about 20% of pregnant and postpartum people. When not treated properly, these issues negatively impact not only affected people, but also their children's health and development. Only 1 in 5 receive adequate treatment, so identifying new system-wide approaches to reliably deliver recommended care to perinatal mental health patients all is a crucial health care priority. The Pregnancy and Postpartum Mental health Optimization Virtual Intervention Network (MOVIN) is a scalable perinatal mental health platform building on the evidence-based Collaborative care delivery model. MOVIN's online platform allows patients to connect with a care coordinator to co-develop personalized treatment recommendations, in collaboration with their primary care clinician and a perinatal psychiatrist when needed; progress is tracked to re-evaluate.
Waitlist Available
Has No Placebo
Women's College Hospital
Image of Mount Sinai Hospital in New York, United States.

Rimegepant + Zavegepant for Migraine

18+
All Sexes
New York, NY
This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting. This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.
Phase 4
Recruiting
Mount Sinai HospitalJonathan SchimmelPfizer
Have you considered Ergomar clinical trials? We made a collection of clinical trials featuring Ergomar, we think they might fit your search criteria.Go to Trials
Image of University of Minnesota in Minneapolis, United States.

Visual Adaptation for Visual Snow

18 - 60
All Sexes
Minneapolis, MN
The goal of this study is to learn more about the brain pathways and activity involved in creating Visual Snow Syndrome (VSS). The main questions it aims to answer are: * Does VSS arise from spontaneous activity in brain pathways? * Where in the brain does the activity contributing to VSS arise? * How does brain activity contribute to VSS? Participants will: 1. Undergo assessments and questionnaires to understand visual and mental symptoms, cognitive, and sensory function. 2. Make visual judgements based on images presented to them both inside and outside a magnetic resonance imaging (MRI) machine. 3. Undergo scanning of their brain while inside of an MRI machine.
Recruiting
Paid Trial
University of MinnesotaMichael-Paul Schallmo, Ph.D.
Image of HCA Florida north florida Hospital in Gainesville, United States.

Bupivacaine Injection for Headache

18+
All Sexes
Gainesville, FL
Headache is a frequent chief complaint among patients presenting to the Emergency Department (ED), accounting for 2.1 million visits annually in the United States. Often, individuals resort to ED care only after over-the-counter or home remedies have failed, leading to the predominant use of intravenous (IV) medications in the ED, including NSAIDs, triptans, neuroleptics, antiepileptics, and dopaminergic antagonists. Unfortunately, these pharmacologic treatments frequently induce side effects such as cognitive impairment, extrapyramidal reactions, and the potential for medication dependency. In the ED, patients frequently require concurrent administration of multiple systemic medications to achieve satisfactory pain relief, thereby elevating the risk associated with medication use. Despite these medication regimens, a significant portion of patients continue to experience inadequate pain relief. Consequently, the search for an optimal headache therapy-characterized by rapid and effective pain relief, long lasting results, minimal side effects, and allows for rapid ED patient turnover-continues to be a popular area of research in emergency medicine. The investigators plan to evaluate the use of 0.5% bupivacaine cervical IM injection at the c6-7 location for the treatment of non traumatic headaches using a non-inferiority design, randomized, prospective, open-label, controlled trial comparing it to physicians choice of intravenous medications in treatment of headache in the Emergency Department at North Florida Hospital.
Phase 3
Waitlist Available
HCA Florida north florida HospitalRobyn Hoelle, MD
Have you considered Ergomar clinical trials? We made a collection of clinical trials featuring Ergomar, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security